schliessen

Filtern

 

Bibliotheken

Oxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria

Background: Patients with primary hyperoxaluria (PH) overproduce oxalate which is eliminated via the kidneys. If end-stage kidney disease develops they are at high risk for systemic oxalosis, unless adequate oxalate is removed during hemodialysis (HD) to equal or exceed ongoing oxalate production. T... Full description

Journal Title: American journal of nephrology 2014-06, Vol.39 (5), p.376-382
Main Author: Tang, Xiaojing
Other Authors: Voskoboev, Nikolay V , Wannarka, Stacie L , Olson, Julie B , Milliner, Dawn S , Lieske, John C
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Basel, Switzerland: S. Karger AG
ID: ISSN: 0250-8095
Link: https://www.ncbi.nlm.nih.gov/pubmed/24776840
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_journals_1544388660
title: Oxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria
format: Article
creator:
  • Tang, Xiaojing
  • Voskoboev, Nikolay V
  • Wannarka, Stacie L
  • Olson, Julie B
  • Milliner, Dawn S
  • Lieske, John C
subjects:
  • Adult
  • Article
  • End stage kidney disease
  • Female
  • Hemodialysis
  • Hemodialysis Solutions - chemistry
  • Humans
  • Hyperoxaluria, Primary - blood
  • Hyperoxaluria, Primary - therapy
  • Hyperoxaluria, Primary - urine
  • Kidney Failure, Chronic - blood
  • Kidney Failure, Chronic - therapy
  • Kidney Failure, Chronic - urine
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Original Report: Patient-Oriented, Translational Research
  • Oxalates - blood
  • Oxalates - isolation & purification
  • Oxalates - urine
  • Oxalosis
  • Primary Hyperoxaluria
  • Renal Dialysis - methods
  • Time Factors
  • Young Adult
ispartof: American journal of nephrology, 2014-06, Vol.39 (5), p.376-382
description: Background: Patients with primary hyperoxaluria (PH) overproduce oxalate which is eliminated via the kidneys. If end-stage kidney disease develops they are at high risk for systemic oxalosis, unless adequate oxalate is removed during hemodialysis (HD) to equal or exceed ongoing oxalate production. The purpose of this study was to validate a method to measure oxalate removal in this unique group of dialysis patients. Methods: Fourteen stable patients with a confirmed diagnosis of PH on HD were included in the study. Oxalate was measured serially in hemodialysate and plasma samples in order to calculate rates of oxalate removal. HD regimens were adjusted according to a given patient's historical oxalate production, amount of oxalate removal at dialysis, residual renal clearance of oxalate, and plasma oxalate levels. Results: After a typical session of HD, plasma oxalate was reduced by 78.4 ± 7.7%. Eight patients performed HD 6 times/week, 2 patients 5 times/week, and 3 patients 3 times/week. Combined oxalate removal by HD and the kidneys was sufficient to match or exceed endogenous oxalate production. After a median period of 9 months, pre-dialysis plasma oxalate was significantly lower than initially (75.1 ± 33.4 vs. 54.8 ± 46.6 mmol/l, p = 0.02). Conclusion: This methodology can be used to individualize the dialysis prescription of PH patients to prevent oxalosis during the time they are maintained on HD and to reduce risk of oxalate injury to a transplanted kidney.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0250-8095
fulltext: fulltext
issn:
  • 0250-8095
  • 1421-9670
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.3696358
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_proquest_journals_1544388660
sourceformatXML
sourcesystemPC
sourcerecordid1534095948
originalsourceidFETCH-LOGICAL-1471t-90cea24b3263fbe36d237bc3f3d7bcafdb9ae31398ba9ddabd0ff10ac588abd43
addsrcrecordideNpdkd1rFDEUxQdRbK0--A_IgCD6sHrzMZnkpbDUj1WKVdBHCXcmNzV1drJNZsT97826dbE-XZL7y8nhnKp6zOAlY415BQBCgeLyTnXMJGcLo1q4Wx0Db2ChwTRH1YOcrwAY19Der464bFulJRxX3y5-4YAT1Z9nHKfgQ49TiGMdxnpF6-gCDtu820-xXuZMOdev_9yFXC8dXc_Yb2sfU_0phTWmbb3abijFIjqngA-rex6HTI9u5kn19e2bL2erxfnFu_dny_MFky2bFgZ6Qi47wZXwHQnluGi7XnjhykDvOoMkmDC6Q-Mcdg68Z4B9o3U5SHFSne51N3O3JtfTOCUc7GbvyUYM9vZmDN_tZfxppdSNAl0EVnuBuKERQ6Jbb91Ik43OctVaQNJCe4OMlDdUgnbkW-4M414zNEXq-Y2XFK9nypNdh9zTMOBIcc6WNUKWSozc_fr0P_QqzmksSRVKSqG1UlCoF3uqTzHnRP7gjYHd9W8P_Rf2yb9BHMi_hRfg2R74gemS0gFYfvjIgRXAADSiVeI3_WO3tA
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1544388660
display
typearticle
titleOxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria
sourceAlma/SFX Local Collection
creatorTang, Xiaojing ; Voskoboev, Nikolay V ; Wannarka, Stacie L ; Olson, Julie B ; Milliner, Dawn S ; Lieske, John C
creatorcontribTang, Xiaojing ; Voskoboev, Nikolay V ; Wannarka, Stacie L ; Olson, Julie B ; Milliner, Dawn S ; Lieske, John C
descriptionBackground: Patients with primary hyperoxaluria (PH) overproduce oxalate which is eliminated via the kidneys. If end-stage kidney disease develops they are at high risk for systemic oxalosis, unless adequate oxalate is removed during hemodialysis (HD) to equal or exceed ongoing oxalate production. The purpose of this study was to validate a method to measure oxalate removal in this unique group of dialysis patients. Methods: Fourteen stable patients with a confirmed diagnosis of PH on HD were included in the study. Oxalate was measured serially in hemodialysate and plasma samples in order to calculate rates of oxalate removal. HD regimens were adjusted according to a given patient's historical oxalate production, amount of oxalate removal at dialysis, residual renal clearance of oxalate, and plasma oxalate levels. Results: After a typical session of HD, plasma oxalate was reduced by 78.4 ± 7.7%. Eight patients performed HD 6 times/week, 2 patients 5 times/week, and 3 patients 3 times/week. Combined oxalate removal by HD and the kidneys was sufficient to match or exceed endogenous oxalate production. After a median period of 9 months, pre-dialysis plasma oxalate was significantly lower than initially (75.1 ± 33.4 vs. 54.8 ± 46.6 mmol/l, p = 0.02). Conclusion: This methodology can be used to individualize the dialysis prescription of PH patients to prevent oxalosis during the time they are maintained on HD and to reduce risk of oxalate injury to a transplanted kidney.
identifier
0ISSN: 0250-8095
1EISSN: 1421-9670
2DOI: 10.1159/000360624
3PMID: 24776840
4CODEN: AJNED9
languageeng
publisherBasel, Switzerland: S. Karger AG
subjectAdult ; Article ; End stage kidney disease ; Female ; Hemodialysis ; Hemodialysis Solutions - chemistry ; Humans ; Hyperoxaluria, Primary - blood ; Hyperoxaluria, Primary - therapy ; Hyperoxaluria, Primary - urine ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - therapy ; Kidney Failure, Chronic - urine ; Kidney Transplantation ; Male ; Middle Aged ; Original Report: Patient-Oriented, Translational Research ; Oxalates - blood ; Oxalates - isolation & purification ; Oxalates - urine ; Oxalosis ; Primary Hyperoxaluria ; Renal Dialysis - methods ; Time Factors ; Young Adult
ispartofAmerican journal of nephrology, 2014-06, Vol.39 (5), p.376-382
rights
02014 S. Karger AG, Basel
1Copyright (c) 2014 S. Karger AG, Basel
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-1471t-90cea24b3263fbe36d237bc3f3d7bcafdb9ae31398ba9ddabd0ff10ac588abd43
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24776840$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Tang, Xiaojing
1Voskoboev, Nikolay V
2Wannarka, Stacie L
3Olson, Julie B
4Milliner, Dawn S
5Lieske, John C
title
0Oxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria
1American journal of nephrology
addtitleAm J Nephrol
descriptionBackground: Patients with primary hyperoxaluria (PH) overproduce oxalate which is eliminated via the kidneys. If end-stage kidney disease develops they are at high risk for systemic oxalosis, unless adequate oxalate is removed during hemodialysis (HD) to equal or exceed ongoing oxalate production. The purpose of this study was to validate a method to measure oxalate removal in this unique group of dialysis patients. Methods: Fourteen stable patients with a confirmed diagnosis of PH on HD were included in the study. Oxalate was measured serially in hemodialysate and plasma samples in order to calculate rates of oxalate removal. HD regimens were adjusted according to a given patient's historical oxalate production, amount of oxalate removal at dialysis, residual renal clearance of oxalate, and plasma oxalate levels. Results: After a typical session of HD, plasma oxalate was reduced by 78.4 ± 7.7%. Eight patients performed HD 6 times/week, 2 patients 5 times/week, and 3 patients 3 times/week. Combined oxalate removal by HD and the kidneys was sufficient to match or exceed endogenous oxalate production. After a median period of 9 months, pre-dialysis plasma oxalate was significantly lower than initially (75.1 ± 33.4 vs. 54.8 ± 46.6 mmol/l, p = 0.02). Conclusion: This methodology can be used to individualize the dialysis prescription of PH patients to prevent oxalosis during the time they are maintained on HD and to reduce risk of oxalate injury to a transplanted kidney.
subject
0Adult
1Article
2End stage kidney disease
3Female
4Hemodialysis
5Hemodialysis Solutions - chemistry
6Humans
7Hyperoxaluria, Primary - blood
8Hyperoxaluria, Primary - therapy
9Hyperoxaluria, Primary - urine
10Kidney Failure, Chronic - blood
11Kidney Failure, Chronic - therapy
12Kidney Failure, Chronic - urine
13Kidney Transplantation
14Male
15Middle Aged
16Original Report: Patient-Oriented, Translational Research
17Oxalates - blood
18Oxalates - isolation & purification
19Oxalates - urine
20Oxalosis
21Primary Hyperoxaluria
22Renal Dialysis - methods
23Time Factors
24Young Adult
issn
00250-8095
11421-9670
fulltexttrue
rsrctypearticle
creationdate2014
recordtypearticle
recordideNpdkd1rFDEUxQdRbK0--A_IgCD6sHrzMZnkpbDUj1WKVdBHCXcmNzV1drJNZsT97826dbE-XZL7y8nhnKp6zOAlY415BQBCgeLyTnXMJGcLo1q4Wx0Db2ChwTRH1YOcrwAY19Der464bFulJRxX3y5-4YAT1Z9nHKfgQ49TiGMdxnpF6-gCDtu820-xXuZMOdev_9yFXC8dXc_Yb2sfU_0phTWmbb3abijFIjqngA-rex6HTI9u5kn19e2bL2erxfnFu_dny_MFky2bFgZ6Qi47wZXwHQnluGi7XnjhykDvOoMkmDC6Q-Mcdg68Z4B9o3U5SHFSne51N3O3JtfTOCUc7GbvyUYM9vZmDN_tZfxppdSNAl0EVnuBuKERQ6Jbb91Ik43OctVaQNJCe4OMlDdUgnbkW-4M414zNEXq-Y2XFK9nypNdh9zTMOBIcc6WNUKWSozc_fr0P_QqzmksSRVKSqG1UlCoF3uqTzHnRP7gjYHd9W8P_Rf2yb9BHMi_hRfg2R74gemS0gFYfvjIgRXAADSiVeI3_WO3tA
startdate201406
enddate201406
creator
0Tang, Xiaojing
1Voskoboev, Nikolay V
2Wannarka, Stacie L
3Olson, Julie B
4Milliner, Dawn S
5Lieske, John C
generalS. Karger AG
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
83V.
97QL
107QP
117RV
127T7
137U9
147X7
157XB
1688E
1788I
188AF
198AO
208FD
218FI
228FJ
238FK
24ABUWG
25AZQEC
26BENPR
27C1K
28DWQXO
29FR3
30FYUFA
31GHDGH
32GNUQQ
33H94
34HCIFZ
35K9.
36KB0
37M0S
38M1P
39M2P
40M7N
41NAPCQ
42P64
43PQEST
44PQQKQ
45PQUKI
46PRINS
47Q9U
48S0X
497X8
50BOBZL
51CLFQK
525PM
sort
creationdate201406
titleOxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria
authorTang, Xiaojing ; Voskoboev, Nikolay V ; Wannarka, Stacie L ; Olson, Julie B ; Milliner, Dawn S ; Lieske, John C
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1471t-90cea24b3263fbe36d237bc3f3d7bcafdb9ae31398ba9ddabd0ff10ac588abd43
rsrctypearticles
prefilterarticles
languageeng
creationdate2014
topic
0Adult
1Article
2End stage kidney disease
3Female
4Hemodialysis
5Hemodialysis Solutions - chemistry
6Humans
7Hyperoxaluria, Primary - blood
8Hyperoxaluria, Primary - therapy
9Hyperoxaluria, Primary - urine
10Kidney Failure, Chronic - blood
11Kidney Failure, Chronic - therapy
12Kidney Failure, Chronic - urine
13Kidney Transplantation
14Male
15Middle Aged
16Original Report: Patient-Oriented, Translational Research
17Oxalates - blood
18Oxalates - isolation & purification
19Oxalates - urine
20Oxalosis
21Primary Hyperoxaluria
22Renal Dialysis - methods
23Time Factors
24Young Adult
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Tang, Xiaojing
1Voskoboev, Nikolay V
2Wannarka, Stacie L
3Olson, Julie B
4Milliner, Dawn S
5Lieske, John C
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7ProQuest Central (Corporate)
8Bacteriology Abstracts (Microbiology B)
9Calcium & Calcified Tissue Abstracts
10Nursing & Allied Health Database
11Industrial and Applied Microbiology Abstracts (Microbiology A)
12Virology and AIDS Abstracts
13Health & Medical Collection
14ProQuest Central (purchase pre-March 2016)
15Medical Database (Alumni Edition)
16Science Database (Alumni Edition)
17STEM Database
18ProQuest Pharma Collection
19Technology Research Database
20Hospital Premium Collection
21Hospital Premium Collection (Alumni Edition)
22ProQuest Central (Alumni) (purchase pre-March 2016)
23ProQuest Central (Alumni Edition)
24ProQuest Central Essentials
25ProQuest Central
26Environmental Sciences and Pollution Management
27ProQuest Central Korea
28Engineering Research Database
29Health Research Premium Collection
30Health Research Premium Collection (Alumni)
31ProQuest Central Student
32AIDS and Cancer Research Abstracts
33SciTech Premium Collection
34ProQuest Health & Medical Complete (Alumni)
35Nursing & Allied Health Database (Alumni Edition)
36Health & Medical Collection (Alumni Edition)
37Medical Database
38Science Database
39Algology Mycology and Protozoology Abstracts (Microbiology C)
40Nursing & Allied Health Premium
41Biotechnology and BioEngineering Abstracts
42ProQuest One Academic Eastern Edition
43ProQuest One Academic
44ProQuest One Academic UKI Edition
45ProQuest Central China
46ProQuest Central Basic
47SIRS Editorial
48MEDLINE - Academic
49OpenAIRE (Open Access)
50OpenAIRE
51PubMed Central (Full Participant titles)
jtitleAmerican journal of nephrology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Tang, Xiaojing
1Voskoboev, Nikolay V
2Wannarka, Stacie L
3Olson, Julie B
4Milliner, Dawn S
5Lieske, John C
formatjournal
genrearticle
ristypeJOUR
atitleOxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria
jtitleAmerican journal of nephrology
addtitleAm J Nephrol
date2014-06
risdate2014
volume39
issue5
spage376
epage382
pages376-382
issn0250-8095
eissn1421-9670
codenAJNED9
abstractBackground: Patients with primary hyperoxaluria (PH) overproduce oxalate which is eliminated via the kidneys. If end-stage kidney disease develops they are at high risk for systemic oxalosis, unless adequate oxalate is removed during hemodialysis (HD) to equal or exceed ongoing oxalate production. The purpose of this study was to validate a method to measure oxalate removal in this unique group of dialysis patients. Methods: Fourteen stable patients with a confirmed diagnosis of PH on HD were included in the study. Oxalate was measured serially in hemodialysate and plasma samples in order to calculate rates of oxalate removal. HD regimens were adjusted according to a given patient's historical oxalate production, amount of oxalate removal at dialysis, residual renal clearance of oxalate, and plasma oxalate levels. Results: After a typical session of HD, plasma oxalate was reduced by 78.4 ± 7.7%. Eight patients performed HD 6 times/week, 2 patients 5 times/week, and 3 patients 3 times/week. Combined oxalate removal by HD and the kidneys was sufficient to match or exceed endogenous oxalate production. After a median period of 9 months, pre-dialysis plasma oxalate was significantly lower than initially (75.1 ± 33.4 vs. 54.8 ± 46.6 mmol/l, p = 0.02). Conclusion: This methodology can be used to individualize the dialysis prescription of PH patients to prevent oxalosis during the time they are maintained on HD and to reduce risk of oxalate injury to a transplanted kidney.
copBasel, Switzerland
pubS. Karger AG
pmid24776840
doi10.1159/000360624
tpages7
oafree_for_read